Medigen Vaccine Biologics Corporation (TPEX:6547)

Taiwan · Delayed Price · Currency is TWD

45.20

-0.30 (-0.66%)

Jun 18, 2026, 1:30 PM CST

-0.44% (1Y)

Market Cap	14.86B -10.8%
Revenue (ttm)	603.68M -8.9%
Net Income	-289.01M
EPS	-0.88
Shares Out	328.75M
PE Ratio	n/a
Forward PE	69.54
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,430,301
Open	45.75
Previous Close	45.50
Day's Range	44.85 - 46.20
52-Week Range	33.50 - 61.20
Beta	-0.09
Analysts	Strong Buy
Price Target	102.00 (+125.66%)
Earnings Date	Aug 13, 2026

About Medigen Vaccine Biologics

Medigen Vaccine Biologics Corporation, a biotechnology drug company, engages in the research, development, and wholesale of vaccines and biopharmaceuticals, and medical devices in Taiwan. It develops enterovirus A71 vaccine, which is in Phase III clinical trial to treat enterovirus infection with severe complications; and Quadrivalent influenza vaccine, which is in Phase III clinical trial for the treatment of influenza viruses. The company also develops dengue vaccines, which has completed Phase II clinical trial to treat dengue; anti respirat... [Read more]

Industry Biotechnology

Sector Healthcare

Founded 2012

Employees 103

Stock Exchange Taipei Exchange

Ticker Symbol 6547

Full Company Profile

Financial Performance

In 2025, Medigen Vaccine Biologics's revenue was 613.17 million, an increase of 1.24% compared to the previous year's 605.64 million. Losses were -281.71 million, 250.1% more than in 2024.

Financial Statements